{"title":"Saxagliptin for patients with T2D and renal impairment","authors":"","doi":"10.1002/fps.74","DOIUrl":null,"url":null,"abstract":"<p><b>Saxagliptin (Onglyza) now offers a further treatment option for patients with type 2 diabetes and moderate to severe renal impairment, improving glycaemic control compared with placebo with a favourable tolerability profile.</b></p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 1","pages":"13"},"PeriodicalIF":0.0000,"publicationDate":"2011-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.74","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.74","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Saxagliptin (Onglyza) now offers a further treatment option for patients with type 2 diabetes and moderate to severe renal impairment, improving glycaemic control compared with placebo with a favourable tolerability profile.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
